CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials

Impact of cytochrome P450 genes on suicide attempt and risk

(2013) Eva M. Peñas-Lledó et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective

(2013) Marc Maliepaard et al.   NATURE REVIEWS DRUG DISCOVERY

The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder

(2012) Peter Höfer et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients

(2012) E M Peñas-LLedó et al.   MOLECULAR PSYCHIATRY

Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects

(2012) S C Sim et al.   PHARMACOGENOMICS JOURNAL

CYP2D6 in the Brain: Impact on Suicidality

(2011) J C Stingl (formerly Kirchheiner) et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders

(2011) E M Peñas-Lledó et al.   MOLECULAR PSYCHIATRY

Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans

(2011) Julia C. Stingl et al.   NEUROIMAGE

CYP2D6and the severity of suicide attempts

(2011) Eva M Peñas-Lledó et al.   PHARMACOGENOMICS

CYP2D6, serotonin, and suicide—a relationship?

(2010) L Bertilsson   CLINICAL PHARMACOLOGY & THERAPEUTICS

CYP2D6 in the brain: genotype effects on resting brain perfusion

(2010) J Kirchheiner et al.   MOLECULAR PSYCHIATRY

CYP2D6 polymorphism in patients with eating disorders

(2010) E M Peñas-LLedó et al.   PHARMACOGENOMICS JOURNAL

High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases

(2009) A L Zackrisson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function

(2009) F. Dutheil et al.   DRUG METABOLISM AND DISPOSITION

The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study

(2009) Ewa Bromek et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

CYP2D6genotyping for psychiatric patients treated with risperidone: considerations for cost–effectiveness studies

(2009) Cristina Rodríguez-Antona et al.   PHARMACOGENOMICS

Relation betweenCYP2D6genotype, personality, neurocognition and overall psychopathology in healthy volunteers

(2009) Eva M Peñas-LLedó et al.   PHARMACOGENOMICS

Association between theCYP2D6*4polymorphism and depression or anxiety in the elderly

(2009) Monique J Bijl et al.   PHARMACOGENOMICS

Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events

(2008) Luis Almeida et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6

(2008) N. T. Snider et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment

(2008) Amandeep Mann et al.   NEUROPHARMACOLOGY

Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers

(2008) Idilio González et al.   PHARMACOGENOMICS

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

(2008) Adrián LLerena et al.   PHARMACOGENOMICS